Vast Therapeutics closes Series A for nitric oxide powder tech

Vast Therapeutics said today that it finished a Series A round with investment from Japan-based Shionogi & Co.

The company plans to use the round’s proceeds to bring their nitric oxide powder technology through preclinical testing and first-in-human clinical safety and efficacy trials.

Vast Therapeutics’ technology, which was in-licensed from the University of North Carolina at Chapel Hill, is designed to combat bacteria that cause respiratory infections. The company’s first focus is to develop a nitric oxide-based drug for cystic fibrosis patients who experience chronic pseudomonas aeruginosa infections.

“Our objective is to completely disrupt the paradigm of treating infections. Our technology can solve a major problem at a time when that problem is creating a dire situation for public health,” Vast’s CEO & chairman, Neal Hunter, said in prepared remarks. “We’ve always realized that it would take more than one company to optimize our technology and Shionogi’s commitment to anti-infectives puts them in a small class of larger pharmaceutical companies who have an ability to develop advanced pharmaceutical products and bring them to market quickly.”

“We’ve had a keen interest in nitric oxide technology for some time. In Vast we have found a technology, intellectual property portfolio, and management team that could help us change the anti-infective market,” Dr. Takeshi Shiota, SVP of Shionogi’s pharmaceutical research division, added.

“From our first meeting with Shionogi earlier this summer, we were impressed with their scientific acumen and research-driven approach to drug development. Regarded as one of the top developers of anti-infective products, Shionogi showed us that they were nimble and capable of working with incredible pace and focus making them the right partner to fully develop nitric oxide pulmonary anti-infectives,” said Vast’s director of business development & IP, Kyle Kimble.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Only a Few More Days to Register for the most anticipated conference of the winter! DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry. Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry. REGISTER NOW Use code LASTCHANCE to save an additional 20%.